Miguel Marques Monteiro

Urology trainee | SantoAntónio, Porto 🇵🇹

[Matt Cooperberg @dr_coops]

New health state definitions for #prostatecancer #PCWG4 ⁦@AarmstrongDuke⁩ #GU26

CSPC -> APMN/APMS
CRPC -> APMR

[Observador @observadorpt]

Em direto/ Vários dirigentes aproximam-se de Lisboa, PSD e PS em campanha mais a Norte https://t.co/H53SQ6G0KD

[Margarida B Lopes @margaridalopes]

📢 O #associativismo estudantil é uma escola de cidadania. A campanha Associa-te valoriza o papel das #Associações de #Estudantes e promove a participação ativa dos #jovens na vida escolar.

[Adam B. Weiner, MD @Adam_Weiner535]

🚨Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder Cancer🚨

👏Landmark trial in urology in @NEJM

😷592 patients randomized

🗓️Median f/u 6.1 years

👉No difference in...
5-year disease-free survival (60% v 56%)
5-year overall survival (63% v 59%)

🔗https://t.co/ltNojB3vHS

@SUO_YUO @UroOnc @urotoday @AmerUrological @renalandurology @UrologyTimes

[Ashish M. Kamat, MD, MBBS @UroDocAsh]

Bladder sparing therapy for BCG–unresponsive
NMIBC: IBCG Recommendations for Optimal Sequencing and Patient Selection

@IBCG_BladderCA #BladderCancer @EUplatinum

Full text: https://t.co/NluKojaIYf

[Félix Guerrero-Ramos @DrFelixGuerrero]

🚨Just published at @Cancers_MDPI
📉#MIBC unsuitable for curative options: poor survival & underserved population 🟰 HIGH UNMET NEED!
🪦OS < 1 year
👓Take a look: https://t.co/AfY9GM4mqo
@Urologia12 @Daniel_Urologia @rojo_esther @cgdelcanizo @MarioHArroyo @MDPIOpenAccess @GUOaeu

[European Urology Open Science @EurUrolOpen]

Review - Prostate Cancer: Enhancing Prostate Cancer Detection Accuracy in Magnetic Resonance Imaging–targeted Prostate Biopsy: Optimizing the Number of Cores Taken by Fabio Zattoni et al

Read full article here: https://t.co/F7Uv9huCRX

#UroSoMe #MedTwitter #PCa #EUROS

[SIU-Urology @SIU_urology]

⏱⏳Less than 48 hours remain until the next #eGrandRounds Update in #StoneManagement. Discover the latest in #PCNL, #MIP, and #fURS procedures. Join us for this free educational event, register today!🔗https://t.co/3cspcVnONW
@emiliani_e @ShashiKiranPal @Endo_Cav @vdconinck

[Kelan tutkimus ja tilastot @Kelantutkimus]

Tammi-heinäkuussa Kela maksoi yksityislääkärikäynneistä korvauksia yli 50 milj. €, eli reilu 30 milj. enemmän kuin viime vuonna vastaavalla ajanjaksolla. Saajia oli 13 000 enemmän.

Päivitimme Kela-korvausseurannan. Uutisessa ja graafissa oli aiemmin virheellinen saajaluku.👇 1/

[Miguel Marques Monteiro @M3Monteiro]

@Mohamedendourol @Tariqaaminia @smasultan62 @dryasser_noor @sbinhamrii Is there any report of urinary fistula after cateterizarion of the tract?

[Enrique Grande @drenriquegrande]

🚨 Exciting Update! 🚨 Our new EVITA (EV Ineligible criTeriA) criteria for identifying patients ineligible for the EV/Pembro combo in #metastaticurothelialcarcinoma has just been published in @EUplatinum!!!! This breakthrough could significantly reshape daily clinical practice! 🩺📈

👉To identify patients who may not be optimal candidates for EV/P if they meet at least two of the following criteria:
📍Hemoglobin A1c 8% (if this parameter is not available itcould be replaced by baseline glucose >150 mg/dl in 2consecutive blood samples 1 wk apart).
📍Grade 2 sensory or motor neuropathy.
📍Any corneal or retinal abnormality.
📍Creatinine clearance or glomerular filtration rate 45
ml/min.
📍ECOG performance status score 2.

A huge thank you to my co-authors and friends @AlisonBirtle and @UroDocAsh for their invaluable contributions in developing these criteria. 🙏

We acknowledge that the EVITA criteria may be a matter of debate and welcome comments and suggestions for improvement from readers. These criteria are based on the expected side effects and exclusion criteria in EV-based clinical trials.

Stay tuned for more data on the EVITA+ population, which will further explore opportunities for new drug development and better characterization of this group. This is an exciting step forward in personalized patient care! #Urology #CancerResearch #EVITACriteria #ClinicalPractice @OncoAlert @urotoday @GuardConsortium @myESMO @Uroweb @EAU_Uroonco @UroTarget @apolo_andrea @ERPlimackMD @giannatempopatr @ravikanesvaran @tompowles1 @PGrivasMDPhD @montypal @amerseburger @cdanicas @sonpavde @DrYukselUrun

Enjoy the reading!!!📑
https://t.co/AN1amYHxAO

[Juan Gómez Rivas @JGomezRivas]

The IDENTIFY @BURSTurology risk calculator predicts urinary tract cancer using patient characteristics.
⭕️It stratifies haematuria patients into very-low-risk, low-risk, intermediate-risk, and high-risk groups.
📈External validation involved 3582 patients, achieving an AUC of 0.78 (0.80 in urothelial cancer prevalent countries).
⚙️Machine learning models, like Random Forest, were evaluated but slightly less effective.
🧮The calculator helps urologists prioritize diagnostics, avoid unnecessary procedures, and better counsel patients.
🦀Most cancers were found in intermediate- and high-risk groups, with more aggressive types in higher-risk groups.
👍This tool aids in fast-tracking high-risk patients for thorough investigations.

https://t.co/ui3w3zUoTK

[Olivier Traxer @OTRAXER]

BN135: When dreams become true. RIRS-Laser with simultaneous suction & pressure control for optimal results: IMMEDIATE STONE FREE, even for volume well above 4000 mm3 (STONE >2 cm). The future is now. Seeing is believing!

[Olivier Traxer @OTRAXER]

BN133: Maybe PCNL is not totally dead at the moment and can still play a major role for huge volume stone, especially when associated with great instrument like Trilogy from EMS. Still alive until…😉😉😉😉😉

[UroToday.com @urotoday]

Is digital rectal examination for the definition of local T-stage still appropriate in the time of MRI and next-generation imaging? Presentation by @declangmurphy @PeterMacCC. #APCCC24 written coverage by @RKSayyid @UofT > https://t.co/jqn6Hof8q1 @APCCC_Lugano

[European School of Urology (EAU ESU) @UrowebESU]

Prof. F. Witjes kicking off the 4th #esumibc24 masterclass on Muscle-invasive bladder cancer in Amsterdam with lectures on diagnosis and treatment and videos of ORC and RARC

[Carlos Guimarães Pinto @cgpliberal]

Quem está convicto de que as suas ideias são melhores que as dos opositores, mantém o combate político ao nível das ideias. Só quem está inseguro em relação às suas ideias recorre a ataques pessoais, insinuações, mentiras e distorções. A utilização dessas tácticas é a maior demonstração de fracasso que uma força política pode ter.

[Zé Pedro Silva @zepiter]

Passos e Portas cometeram um erro que ainda se está a pagar. Era o PS que tinha de implementar todas as medidas duras. A pressa que tinham, perante tão grande oportunidade, deu azo à proeza de ficarem com o trabalho sujo, numa jogada que mandou a direita para o estaleiro.

Não foi patriotismo algum, não sejamos piegas. Foi poder. Podia ter-se esticado mais a corda e deixado o PS a implementar a dose toda e a assumir a responsabilidade pela situação em que o país se encontrava. Era ver se metiam as pernas dos banqueiros alemães a tremer ou se, afinal, também iam além da Troika.

Pedir o leme, naquele momento, está entre as piores decisões das últimas décadas.

A história teria sido completamente diferente se tivessem deixado o PS a resolver o problema, viabilizando-lhes patrioticamente os PEC e as troikas todas. Nem o receio de fazerem ainda pior existia - razão pela qual não se trata de patriotismo -, pois já estávamos sob domínio.

Se tivessem esperado por 2013, ainda hoje estavam no poder e também deviam vencer as eleições de 2025.

Em vez disso, deixa lá ver se vencem estas, porque ainda há muito eleitorado que não lhes perdoa tantas maldades. E com razão. Eles é que quiserem muito governar quatro aninhos sem um tostão e a saberem que tinham, de uma forma ou de outra, de esfolar o povo.

Tenho respeito pelo que fizeram, mas gosto sempre de lembrar os nabos que foram.

[Iniciativa Liberal @LiberalPT]

⚠️ NÃO FUNCIONA, PEDRO!

[Miguel Marques Monteiro @M3Monteiro]

@reis_bugalho Não Funciona, Pedro